Eli Lilly and Company (NYSE:LLY) Stock Holdings Reduced by Auxano Advisors LLC

Auxano Advisors LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,457 shares of the company’s stock after selling 72 shares during the period. Auxano Advisors LLC’s holdings in Eli Lilly and Company were worth $849,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. JGP Wealth Management LLC grew its position in Eli Lilly and Company by 0.9% in the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after acquiring an additional 16 shares in the last quarter. Patton Albertson Miller Group LLC boosted its holdings in Eli Lilly and Company by 2.8% in the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after purchasing an additional 17 shares in the last quarter. Valley Wealth Managers Inc. increased its position in Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after buying an additional 17 shares during the last quarter. Sandy Cove Advisors LLC increased its position in Eli Lilly and Company by 0.8% during the fourth quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock worth $1,307,000 after buying an additional 17 shares during the last quarter. Finally, Lathrop Investment Management Corp lifted its position in shares of Eli Lilly and Company by 1.2% in the third quarter. Lathrop Investment Management Corp now owns 1,476 shares of the company’s stock worth $793,000 after buying an additional 18 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on LLY shares. Citigroup increased their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Morgan Stanley increased their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Truist Financial reissued a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. BMO Capital Markets increased their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Finally, Wells Fargo & Company increased their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $731.55.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $43.90 during mid-day trading on Tuesday, reaching $781.10. The stock had a trading volume of 7,345,096 shares, compared to its average volume of 3,069,532. The firm’s 50 day simple moving average is $760.89 and its 200 day simple moving average is $668.00. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a one year low of $392.26 and a one year high of $800.78. The firm has a market cap of $742.17 billion, a PE ratio of 134.43, a P/E/G ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the company earned $2.09 EPS. On average, analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.